Electroencephalographical effects of sarpogrelate hydrochloride versus ticlopidine hydrochloride in elderly patients with peripheral atherosclerosis.
The aim was to determine the efficacy of sarpogrelate (a selective 5-hydroxytryptamine-2-serotonergic receptor antagonist) on cerebrovascular function and mean blood pressure (mBP) in elderly patients (> 60 years old). Patients with peripheral circulatory disorders were studied using electroencephalogram (EEG) and mBP measurements before and after 2 years' treatment with either sarpogrelate (n = 31) or ticlopidine (n = 43). Ticlopidine had no significant effect on the whole brain. Sarpogrelate decreased the percentage of slow waves (%slow), but not significantly, and was associated with a smaller change in the percentage of slow waves (delta slow). In the anterior area, neither drug caused significant EEG changes. In the posterior area, sarpogrelate significantly decreased the %slow and increased the %alpha values, and was associated with a significantly higher delta alpha value than ticlopidine. The results suggest that sarpogrelate hydrochloride can suppress serotonin-induced pathological processes in peripheral circulatory disorders and may be recommended as an anti-platelet agent, even in elderly patients with subclinical arteriosclerosis.
Iwakuma
H
H
Fukuoka Prefectural Onga Hospital, Fukuoka, Japan.
D000368:Aged; D000369:Aged, 80 and over; D001161:Arteriosclerosis / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects; D002560:Cerebrovascular Circulation / Q000187:drug effects; D004569:Electroencephalography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D044348:Receptors, Serotonin, 5-HT2 / Q000378:metabolism; D012702:Serotonin Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D013223:Statistics as Topic; D013386:Succinates / Q000494:pharmacology / Q000627:therapeutic use; D013988:Ticlopidine / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D044348:Receptors, Serotonin, 5-HT2; D012702:Serotonin Antagonists; D013386:Succinates; C064294:sarpogrelate; D013988:Ticlopidine